{
    "clinical_study": {
        "@rank": "163222", 
        "arm_group": [
            {
                "arm_group_label": "e-vapour product (EVP)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP)."
            }, 
            {
                "arm_group_label": "Conventional cigarette (CC)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects who continue smoking their usual conventional cigarette (CC) brand."
            }
        ], 
        "brief_summary": {
            "textblock": "Electronic Vapour Products (EVPs) is a relatively new class of consumer products that are\n      otherwise known as electronic cigarettes or electronic nicotine delivery devices/systems.\n      These may look like conventional cigarettes but do not contain tobacco.\n\n      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or\n      glycerol), nicotine, water, and flavours.\n\n      This trial is to evaluate the safety and tolerability of an e-vapour product."
        }, 
        "brief_title": "A Study to Evaluate the Safety Profile of an e-Vapour Product", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI of 18-35kg/m2\n\n          -  Subjects must be established smokers\n\n          -  Subjects must have smoked five to 30 cigarettes per day for at least one year\n\n        Exclusion Criteria:\n\n          -  Subjects who have used nicotine replacement therapy within 14 days of the screening\n\n          -  Subjects who have donated blood within 12 months preceding study\n\n          -  Subjects with relevant illness history\n\n          -  Subjects positive for hepatitis or HIV\n\n          -  Subjects with history of drug or alcohol abuse\n\n          -  Subjects with lung function test or vital signs considered unsuitable\n\n          -  Subjects who are trying to stop smoking\n\n          -  Female subjects who are pregnant, or unwilling to use acceptable contraceptive method\n             for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029196", 
            "org_study_id": "ITG EVP G1 S2"
        }, 
        "intervention": [
            {
                "arm_group_label": "e-vapour product (EVP)", 
                "intervention_name": "E-vapour product", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Conventional cigarette (CC)", 
                "intervention_name": "Conventional cigarette", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "robert.turner_cain@convance.com", 
                    "last_name": "Robert Turner-Cain, BA, MBA", 
                    "phone": "+44 (0)113 2373500", 
                    "phone_ext": "2130"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "LS2 9HL"
                    }, 
                    "name": "Covance Clinical Research Unit"
                }, 
                "investigator": {
                    "last_name": "Jim Bush, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oliver.knott@simbec.co.uk", 
                    "last_name": "Oliver Knott, MSc", 
                    "phone": "+44 (0) 1443 694317"
                }, 
                "facility": {
                    "address": {
                        "city": "Merthyr Tydfil", 
                        "country": "United Kingdom", 
                        "state": "Wales", 
                        "zip": "CF48 4DR"
                    }, 
                    "name": "Simbec Research"
                }, 
                "investigator": {
                    "last_name": "Girish Sharma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product", 
        "overall_contact": {
            "email": "robert.turner_cain@covance.com", 
            "last_name": "Robert Turner-Cain, BA, MBA", 
            "phone": "+44 (0)113 2373500", 
            "phone_ext": "2130"
        }, 
        "overall_contact_backup": {
            "email": "oliver.knott@simbec.co.uk", 
            "last_name": "Oliver Knott, MSc", 
            "phone": "+44 (0)1443 694317"
        }, 
        "overall_official": [
            {
                "affiliation": "Covance Clinical Research Unit, Springfield House, Hyde Street, Leeds LS2 9LH, UK", 
                "last_name": "Jim Bush, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Simbec Research, Merthyr Tydfil, CF48 4DR, UK", 
                "last_name": "Girish Sharma, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: South East Wales Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "ECG", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Lung Function Testing", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Clinical laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029196"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Craving and withdrawal symptoms", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Carboxyhaemoglobin", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "High-density lipoprotein cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Imperial Tobacco Group PLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imperial Tobacco Group PLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}